GPCRs in Cancer: Protease-Activated Receptors, Endocytic Adaptors and Signaling

Abstract

G protein-coupled receptors (GPCRs) are a large diverse family of cell surface signaling receptors implicated in various types of cancers. Several studies indicate that GPCRs control many aspects of cancer progression including tumor growth, invasion, migration, survival and metastasis. While it is known that GPCR activity can be altered in cancer through aberrant overexpression, gain-of-function activating mutations, and increased production and secretion of agonists, the precise mechanisms of how GPCRs contribute to cancer progression remains elusive. Protease-activated receptors (PARs) are a unique class of GPCRs implicated in cancer. PARs are a subfamily of GPCRs comprised of four members that are irreversibly activated by proteolytic cleavage induced by various proteases generated in the tumor microenvironment. Given the unusual proteolytic irreversible activation of PARs, expression of receptors at the cell surface is a key feature that influences signaling responses and is exquisitely controlled by endocytic adaptor proteins. Here, we discuss new survey data from the Cancer Genome Atlas and the Genotype-Tissue Expression projects analysis of expression of all PAR family member expression in human tumor samples as well as the role and function of the endocytic sorting machinery that controls PAR expression and signaling of PARs in normal cells and in cancer.

Prostanoid receptor genes confer poor prognosis in head and neck squamous cell carcinoma via epigenetic inactivation

“…Key therapeutic applications involving GPCRs include opioid analgesics, antihistamines, anticholinergics, typical and atypical antipsychotics, antimigraine drugs, β2-agonists for asthma, and anti-hypertensives [8]. However, anti-cancer drugs that specifically target GPCRs are not currently available [9]. The prostanoid receptors represent the most notable family of validated pharmacological targets in a variety of diseases, including cancer [10].…”

Possible association of arrestin domain-containing protein 3 and progression of non-alcoholic fatty liver disease

“…Recent studies demonstrated that ARRDC3 also play roles in human cancer signaling [54,55]. We identified ARRDC3 as an important positive regulator in NAFLD and NASH.…”

The oncolytic virus H101 combined with GNAQ siRNA‐mediated knockdown reduces uveal melanoma cell viability

“…Different types of melanomas occur because of various mutations. 16,17 The signaling pathways downstream from GPCR include the activation of protein kinase C family members and the release of diacylglycerol. 12,13 G-protein-coupled receptor (GPCR) proteins comprise a diverse family of transmembrane receptors, which exert a function of transducing signal from extracellular environment to the cellular interior.…”